Result of AGM
RNS & Investor News
Grant of Options
31 March 2015
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.
The table below shows the details of the options granted to directors:
|Director||Number of options granted||Exercise Price|
All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.
Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
|Tel: 020 7148 7900|
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020